<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004277.pub2" GROUP_ID="IBD" ID="508303011613241169" MERGED_FROM="" MODIFIED="2008-07-15 18:46:50 +0200" MODIFIED_BY="John MacDonald" REVIEW_NO="56" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-07-15 18:46:50 +0200" MODIFIED_BY="John MacDonald">
<TITLE>Cyclosporine A for induction of remission in severe ulcerative colitis</TITLE>
<CONTACT MODIFIED="2008-07-15 18:46:50 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="14364" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Oren</FIRST_NAME><LAST_NAME>Shibolet</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>shibolet@hadassah.org.il; oshibolet@partners.org</EMAIL_1><ADDRESS><DEPARTMENT>Gastroenterology Unit GRJ715</DEPARTMENT><ORGANISATION>Massachusetts General Hospital</ORGANISATION><ADDRESS_1>55 Fruit Street</ADDRESS_1><CITY>Boston</CITY><ZIP>04122</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-15 18:46:50 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="14364" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Oren</FIRST_NAME><LAST_NAME>Shibolet</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>shibolet@hadassah.org.il; oshibolet@partners.org</EMAIL_1><ADDRESS><DEPARTMENT>Gastroenterology Unit GRJ715</DEPARTMENT><ORGANISATION>Massachusetts General Hospital</ORGANISATION><ADDRESS_1>55 Fruit Street</ADDRESS_1><CITY>Boston</CITY><ZIP>04122</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="14362" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elena</FIRST_NAME><LAST_NAME>Regushevskaya</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>elenregu@hotmail.com, helenny@yandex.ru</EMAIL_1><ADDRESS><ORGANISATION>Medical Academy of Postgraduate Studies</ORGANISATION><ADDRESS_1>Kirochnaya 41</ADDRESS_1><CITY>St. Petersburg</CITY><ZIP>193015</ZIP><COUNTRY CODE="RU">Russia</COUNTRY><PHONE_1>7 812 598 9320</PHONE_1><FAX_1>7 812 598 9320</FAX_1></ADDRESS></PERSON><PERSON ID="13982" ROLE="AUTHOR"><PREFIX>Professor</PREFIX><FIRST_NAME>Mayer </FIRST_NAME><LAST_NAME>Brezis</LAST_NAME><EMAIL_1>brezis@vms.huji.ac.il</EMAIL_1><ADDRESS><DEPARTMENT>Center for Clinical Quality &amp; Safety</DEPARTMENT><ORGANISATION>Hadassah Hebrew University Hospital</ORGANISATION><ADDRESS_1>Ein Kerem Campus Box 53 </ADDRESS_1><ADDRESS_2>POB 12000</ADDRESS_2><CITY>Jerusalem</CITY><ZIP>91120</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 2 677 7110 </PHONE_1><PHONE_2>+972 2 50 787 4596 </PHONE_2></ADDRESS></PERSON><PERSON ID="12341" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Karla</FIRST_NAME><LAST_NAME>Soares-Weiser</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Director</POSITION><EMAIL_1>karla@enhance-reviews.com</EMAIL_1><EMAIL_2>ksoares@netvision.net.il</EMAIL_2><URL>www.enhance-reviews.com</URL><ADDRESS><ORGANISATION>Enhance Reviews</ORGANISATION><ADDRESS_1>PO Box 137</ADDRESS_1><CITY>Kfar-Saba</CITY><ZIP>44101</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 9 767 3223</PHONE_1><FAX_1>+972 9 767 0103</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-15 12:40:42 -0400" MODIFIED_BY="John K MacDonald">
<UP_TO_DATE>
<DATE DAY="14" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="7" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2008-07-15 12:35:08 -0400" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="15" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 12:35:08 -0400" MODIFIED_BY="John K MacDonald">
<DATE DAY="14" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>New literature search did not identify any new studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Cyclosporine A for induction of remission in severe ulcerative colitis</TITLE>
<SUMMARY_BODY>
<P>Ulcerative colitis (UC) is a chronic inflammation of the large bowel. Symptoms include bloody diarrhea and abdominal pain. The disease can also have manifestations outside the bowel with involvement of the joints, skin, eyes and liver. While the 'first line' treatment for a severe attack of UC is usually steroids (either as pills or intravenously) the options for patients not responding to steroids are limited and include surgical removal of the large bowel. Cyclosporine A (CsA), a drug effective in preventing transplant organ rejection by suppressing the immune system, was tried in severe UC with encouraging results in the early 1990's. The aim of this review was to assess the effectiveness of CsA for severe UC. The literature search identified 36 studies. Only 2 studies were of high methodological quality and both support the use of CsA in UC patients with a severe attack. However, both studies were small (involving only 50 patients altogether) and limited in the length of follow-up (from a few weeks up to a year). There is limited evidence that cyclosporine is more effective than standard treatment for severe ulcerative colitis. The conclusion of the review is that while the data concerning the use of CsA in severe UC are encouraging, more studies are needed. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Ulcerative colitis (UC) is characterized by a life-long chronic course with remissions and exacerbations. Approximately 15% of patients have a severe attack requiring hospitalization at some time during their illness. These patients are traditionally treated with intravenous corticosteroids, with a response rate of approximately 60%. The patients who do not respond to steroid treatment usually require surgical removal of the large bowel (proctocolectomy or colectomy with an anal pouch). This surgical procedure essentially cures the patient from the disease but is associated with complications such as pouchitis. Few alternative treatments exist for severe ulcerative colitis: immunosuppressive medications (such as azathioprine) have a slow onset of action and are therefore usually ineffective. Antibiotics are not proven to be effective and biological treatments such as infliximab are still under investigation. The introduction of cyclosporine-A (CsA) for use in patients with severe ulcerative colitis (UC) has provided an alternative to patients previously facing only surgical options. Cyclosporine acts mainly by inhibiting T lymphocyte function, which is essential for the propagation of inflammation. Unlike most other immunosuppressive agents, CsA does not suppress the activity of other hematopoietic cells, does not cause bone marrow suppression and has a rapid onset of action. This reviews aims to systematically assess the effectiveness and safety of CsA for severe UC. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>This review aimed to evaluate the effectiveness of cyclosporine A for patients with severe ulcerative colitis. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches of The Cochrane Library (Issue 2, 2008), EMBASE (1980-2008), and MEDLINE (1966-2008); hand searching the references of all identified studies; contacting the first author of each included trial.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing cyclosporine A with placebo or no intervention to obtain and maintain remission of idiopathic ulcerative colitis. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently appraised the quality of each trial and extracted the data from the included trials. Relative risks (RR) with 95% confidence intervals (CI) were estimated. The reviewers assumed an intention to treat analysis for the outcome measures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>An updated literature search performed in July 2008 did not identify any new trials. Only two randomized controlled trials were identified that satisfied the inclusion criteria. These two trials could not be pooled for analysis because of major differences in design and patient populations. In the first trial, 11 patients received intravenous cyclosporine (4 mg/kg) and 9 received placebo. Two of 11 in the treatment group failed to respond to therapy compared with nine of nine in the placebo group (RR 0.18, 95% CI 0.05 - 0.64). However, 3/11 and 4/9 eventually underwent colectomy in the treatment and placebo groups respectively and follow-up was less than a month. In the second trial 15 patients were treated with intravenous cyclosporine and 15 with intravenous methylprednisolone. Five of 15 patients in the cyclosporine group failed to respond to therapy as compared to 7/15 in the methylprednisolone group (RR 0.71, 95% CI 0.29 - 1.75). After 1 year 7/9 responders in the cyclosporine group were still in remission compared with 4/8 in the steroid group (p &gt; 0.05) and the colectomy rate was similar in both groups. The mean time to response in the cyclosporine group in the 2 trials was short (7 days and 5.2 days). These results should be interpreted with caution given the small numbers of trials and patients evaluated for comparison, and limited follow-up (few weeks in one trial to a year in the other). The precise assessment of the occurrence of adverse events was difficult because the trials described different adverse reactions, which reversed after discontinuation of cyclosporine. There was no evidence in the trials reviewed that cyclosporine was more effective than standard treatment for preventing colectomy but this effect cannot be excluded due to the small sample size and rarity of this outcome. Additional limitations of current research include lack of data on quality of life, costs and long-term results of cyclosporine therapy. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is limited evidence that cyclosporine is more effective than standard treatment alone for severe ulcerative colitis. The relatively quick response makes the short-term use of cyclosporine potentially attractive, but the long-term benefit is unclear, when adverse events such as cyclosporine-induced nephrotoxicity may become more obvious. There is a need for additional research on quality of life, costs and long-term results from cyclosporine therapy in severe ulcerative colitis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Ulcerative colitis is an inflammatory disease involving the large bowel. The disease is characterized by a life-long chronic course with remissions and exacerbations (<LINK REF="REF-Podolsky--2002" TYPE="REFERENCE">Podolsky 2002</LINK>). The intestinal manifestations of the disease are abdominal pain and bloody diarrhea, there are also extra-intestinal manifestations involving joints, skin, eyes and liver. Approximately 15% of patients have a severe attack requiring hospitalization at some time during their illness. These patients are traditionally treated with intravenous corticosteroids, with a response rate of approximately 60% (<LINK REF="REF-Blomberg-2000" TYPE="REFERENCE">Blomberg 2000</LINK>). The patients who do not respond to steroid treatment usually require surgical removal of the large bowel (proctocolectomy or colectomy with an anal pouch). This surgical procedure essentially cures the patient from this disease but is associated with some complications such as pouchitis and infection (<LINK REF="REF-Blumberg-2002" TYPE="REFERENCE">Blumberg 2002</LINK>; <LINK REF="REF-Pikarsky-2002" TYPE="REFERENCE">Pikarsky 2002</LINK>). Few alternative treatments exist for severe steroid-resistant ulcerative colitis: immunosuppressive medications which may be effective for long-term management, (such as azathioprine) have a slow onset of action and are therefore usually ineffective in the acute setting (<LINK REF="REF-Hyde-1997" TYPE="REFERENCE">Hyde 1997</LINK>). Antibiotics are not proven to be effective (<LINK REF="REF-Mantzaris-2001" TYPE="REFERENCE">Mantzaris 2001</LINK>; <LINK REF="REF-Mantzaris-1994" TYPE="REFERENCE">Mantzaris 1994</LINK>). New biological treatments such as cytokines or monoclonal antibodies against cytokines, (e.g. anti-TNF antibodies (infliximab) or IL-10) are still under investigation (<LINK REF="REF-Gornet-2003" TYPE="REFERENCE">Gornet 2003</LINK>; <LINK REF="REF-Probert-2003" TYPE="REFERENCE">Probert 2003</LINK>; <LINK REF="REF-Schreiber--1998" TYPE="REFERENCE">Schreiber 1998</LINK>).</P>
<P>The introduction of cyclosporine-A (CsA) for use in patients with severe ulcerative colitis (UC) has provided a new medical alternative to patients previously faced with only surgical options (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>; <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK>). Cyclosporine acts mainly by inhibiting T lymphocyte function, which is essential for the propagation of inflammation. Unlike most other immunosuppressive agents, CsA does not suppress the activity of other stem cells, does not cause bone marrow suppression and has a rapid onset of action (<LINK REF="STD-Cohen-1999b" TYPE="STUDY">Cohen 1999b</LINK>; <LINK REF="REF-Ina-2002" TYPE="REFERENCE">Ina 2002</LINK>). Since the first placebo controlled trial of CsA in UC was published, more experience has been gained with CsA in severe UC, but its effectiveness and safety and its effect on quality of life (<LINK REF="STD-Cohen-1999a" TYPE="STUDY">Cohen 1999a</LINK>) have not been systematically assessed and there is still controversy concerning its use (<LINK REF="REF-Haslam-2000" TYPE="REFERENCE">Haslam 2000</LINK>; <LINK REF="REF-Hyde-2001" TYPE="REFERENCE">Hyde 2001</LINK>; <LINK REF="REF-Hyde-1998" TYPE="REFERENCE">Hyde 1998</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>This review aimed to evaluate the effectiveness of cyclosporine A in patients with severe ulcerative colitis. We intended to estimate the mortality, frequency of induction of remission, and the frequency of adverse effects associated with the use of cyclosporine A.<BR/>More specifically, this review intended to answer the following relevant questions:<BR/>1. Is cyclosporine A effective in preventing death in patients with severe acute ulcerative colitis?<BR/>2. Is cyclosporine A effective in induction of remission of ulcerative colitis in patients with severe acute ulcerative colitis?<BR/>3. Is cyclosporine A effective in preventing colectomy in patients with severe acute ulcerative colitis?<BR/>4. How frequent and severe are adverse events of cyclosporine A in ulcerative colitis?</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised clinical trials comparing the addition of cyclosporine A to standard treatment with standard treatment alone in patients with severe ulcerative colitis. Trials were included irrespective of publication status, language, and blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult patients (18 + years of age) with severe ulcerative colitis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intervention: Cyclosporine A was considered, regardless of the mode of administration (intravenous, oral or enema). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The number of patients with clinical improvement or remission of severe ulcerative colitis was used as the outcome measure of interest. The definition of improvement and remission was based on the modified Truelove and Witts score (<LINK REF="REF-Truelove-1955" TYPE="REFERENCE">Truelove 1955</LINK>). The primary outcome measures was the number of patients that did not have remission of symptoms of ulcerative colitis.</P>
<P>Secondary outcome measures included:<BR/>1. the number of deaths;<BR/>2. the number of patients who required surgery; and<BR/>3. adverse events.</P>
<P>Adverse events included:<BR/>1. any serious adverse events that were fatal, life-threatening, or requiring inpatient hospitalisation or prolongation of existing hospitalisation;<BR/>2. any adverse events that resulted in significant disability or incapacity;<BR/>3. any important medical events that might not be immediately life-threatening or resulted in death or hospitalisation, but might jeopardise the patient or required intervention to prevent one of the above outcomes; and<BR/>4. any adverse events that required discontinuation of medication.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>A computer-assisted search of the bibliographic databases MEDLINE (January 1996 to July 2008), the Cochrane Library (Issue 2, 2008) and EMBASE (January 1980 to July 2008), was carried out to identify relevant studies. The search performed with the phrase:<BR/>["cyclosporine A" or Cyclosporin A and "ulcerative colitis] (Cyclosporine:*ME or Cyclosporin*) AND (Colitis Ulcerative:* ME OR (Colitis and ulcerative)) (Sandimmun, Novartis), (Sandimmun Neoral, Novartis), (Sangcya, Eli Lilly &amp; Co). </P>
<P>The references of all identified studies were inspected for more trials. Additionally, the first or corresponding author of each included trial and the researchers active in the field were contacted for information regarding unpublished trials or complementary information on their own trial.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Study selection<BR/>Two reviewers (OS, ER) independently inspected each reference identified by the search and applied the inclusion criteria. For possible relevant articles, or in cases of disagreement between the two reviewers, the full article was obtained and inspected independently by the two reviewers. Where resolving disagreement by discussion was not possible, the article was added to those 'awaiting assessment' and the authors of the study were contacted for clarification. In an event of no reply from the authors within three months, a third reviewer (MB or KSW) checked the article to solve the disagreements. Justification for excluding studies from the review was also documented. </P>
<P>Quality assessment <BR/>Trials fulfilling the review inclusion criteria were assessed for methodological quality by two reviewers (OS, ER). We extracted information about randomisation and allocation concealment, blinding, sample size, exclusions after randomisation, and different lengths of follow-up. However, trials were assessed based on the empirical evidence of a strong association between poor allocation concealment and overestimation of effect (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>; <LINK REF="REF-Schulz--1995" TYPE="REFERENCE">Schulz 1995</LINK>). This was defined as below: <BR/>A. low risk of bias (adequate allocation concealment);<BR/>B. moderate risk of bias (unclear allocation concealment); and<BR/>C. high risk of bias (inadequate allocation concealment, i.e., quasi-randomised studies).<BR/>For the purpose of the analyses in this review, trials were included if they meet the criteria A or B in the Cochrane Reviewers' Handbook (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>; <LINK REF="REF-Kunz-1998" TYPE="REFERENCE">Kunz 1998</LINK>). </P>
<P>Data collection<BR/>Two reviewers (OS, ER) independently extracted the data of included trials. In case of any disagreement between the two reviewers, a third reviewer (MB or KSW) extracted the data. The data extraction was discussed, decisions documented and, where necessary, the authors of the trials were contacted for clarification. Trials were identified by the name of the first author and year in which the trial was first published and ordered chronologically. </P>
<P>Data synthesis<BR/>Dichotomous data were analysed by calculating the relative risk (RR) for each trial with the uncertainty in each result being expressed using 95% confidence intervals (CI). </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>An updated literature search performed in July 2008 did not identify any new trials. Thirty six references were reviewed. Two trials were identified that satisfied the inclusion criteria (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>; <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK>). Both studies were randomized controlled double-blind trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>An independent assessment of the quality of each eligible study was performed by two reviewers (ER and OS) Neither of the two included studies provided enough information to assess the adequacy of allocation concealment and both were initially rated as 'B' or unclear allocation concealment. The study authors were contacted for further information and both responded. As a result both of the included studies were rated as 'A' for adequate allocation concealment. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK> enrolled 20 steroid refractory patients and eleven received cyclosporine and nine received placebo. Response was defined as a decline in the clinical activity index score to less than 10 [modified Truelove and Witts clinical activity index (<LINK REF="REF-Truelove-1955" TYPE="REFERENCE">Truelove 1955</LINK>)]. The index attributes points to clinical parameters including diarrhea, visible blood in the stool, fecal incontinence, abdominal pain or cramping, general well-being, abdominal tenderness and need for antidiarrheal drugs. All patients were assessed on an intention-to-treat basis. Nine of the 11 patients (82%) in the intravenous cyclosporine group had a response to therapy in comparison with none of 9 patients in the placebo group. The relative risk of no induction of remission was 0.18 (95% CI 0.05 - 0.64). </P>
<P>
<LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> enrolled 30 patients with severe ulcerative colitis and fifteen patients were treated with methylprednisolone and fifteen with cyclosporine. One patient in the cyclosporine group was found to have <I>Clostridium difficile</I> toxins in the feces and was withdrawn from the trial. This patient is included in the intention to treat analysis. Response to therapy was defined as improvement in clinical-activity score at the end of the treatment (to less than 10). Nine of 15 patients (60%) had a response to cyclosporine compared with 8 of 15 (53%) to methylprednisolone. The relative risk of no induction of remission was 0.71 (95% CI 0.29 - 1.75). One patient from the placebo group (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>) who underwent colectomy died after the end of the study because of the gram-negative sepsis with superimposed cytomegalovirus infection. </P>
<P>In the first study (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>), the colectomy rate was 3/11 (27%) for the intervention group and 4/9 (44%) for placebo group with relative risk 0.6 (95% CI 0.18-2.06). In the <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> study the colectomy rate was 3/15 (20%) in the cyclosporine group compared to 3/15 patients in the methylprednisolone group (RR 1.0, 95% CI 0.24 - 4.18). At one year follow-up the colectomy rate was 5/15 (33%) and 6/15 (40%) in the cyclosporine and methylprednisolone group respectively.</P>
<P>Adverse effects were difficult to assess because the authors described different adverse effects that were not comparable. The main adverse events described in both studies were hypertension, defined as a systolic blood pressure more than 140 mm Hg or a diastolic blood pressure of more than 90 mm Hg for two consecutive days, paresthesias and vomiting. Neither trial identified any statistically significant differences in adverse events (e.g. death, parasthesias, hypertension and vomiting). The rate of paresthesias in the <LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK> study was 4/11 (36%) as compared with none of the patients in the placebo group. In the <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> study paresthesias occurred in one patient in the control group and in none of the patients who received cyclosporine (<LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK>). The hypertension rate was 4/11 (36%) in the intervention group and one patient in the placebo group (11%) (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>). In the <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> study hypertension occurred in one patient receiving cyclosporine (6%) and none of the patients treated with methylprednisolone. Vomiting occurred in one patient in each group in the study described by <LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK> and in one patient who received cyclosporine in the <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> study. No patients in either study developed nephrotoxicity. This can probably be attributed the short-term therapy (8-14 days) and the fact that cyclosporine levels were monitored frequently. <BR/>One patient treated with cyclosporine (<LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK>) had a grand mal seizure after the initiation of therapy and had no more seizures after cyclosporine discontinuation. This patient had hypocholesterolemia. Other adverse reactions (gingival hyperplasia, tremor and hair loss) in patients who received cyclosporine were rare and described as mild and transient. Such assessment can be made only for short-term cyclosporine treatment (8-14 days). In the <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> study four patients in the treatment group had hypokalemia and 2 had hypomagnesemia as compared to none in the methylprednisolone group. There were no patients in either study who had infectious complications. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>It was not appropriate to combine the data from these two studies since the design was not similar. <LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK> compared cyclosporine to placebo and <LINK REF="STD-D_x0027_Haens-2001" TYPE="STUDY">D'Haens 2001</LINK> compared cyclosporine and steroids to steroids alone. Also, the patient groups were not comparable, those in the <LINK REF="STD-Lichtiger-1994" TYPE="STUDY">Lichtiger 1994</LINK> study being defined as steroid refractory. </P>
<P>Therefore we conclude that the data currently available are not sufficient, to suggest that cyclosporine is better than placebo or steroids for patients with severe ulcerative colitis. The results of the two trials should be interpreted with caution given the small numbers of patients evaluated for comparison, and the limited follow-up ranging from a few weeks in one trial to a year in the other. Additional limitations of these studies are lack of data on quality of life, cost of adding cyclosporine to the standard treatment and long-term results of the cyclosporine therapy. In both studies the long-term effects were described for very few patients who received cyclosporine in open-label fashion. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is limited evidence that cyclosporine is more effective than standard treatment for severe ulcerative colitis. In two randomized controlled trials on 50 patients (26 treated with cyclosporine), cyclosporine appears to reduce the clinical activity of disease. The mean time to response (within days) is relatively rapid and makes the use of cyclosporine in severe ulcerative colitis patients potentially attractive. Short-term cyclosporine therapy may be attempted in cases of severe ulcerative colitis, where surgery is the only option, but is not based on strong evidence. The recommendation is based on the fact that the time to response was short and adverse effects of cyclosporine were mild and disappeared after discontinuation of the treatment. Adverse effects such as nephrotoxicity should be taken into consideration, especially if longer duration of cyclosporine therapy is contemplated. There is no evidence in the trials reviewed that cyclosporine is more effective than the standard treatment in terms of colectomy rate, but this effect cannot be excluded due to the small numbers of patients studied and rarity of this outcome.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Trials of good quality are needed to assess induction of remission, improvement of colectomy rate, the quality of life, cost of adding cyclosporine to the standard treatment and long-term effects of cyclosporine therapy in patients with severe ulcerative colitis. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity.</P>
<P>Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Oren Shibolet: protocol writing, searching, trial selection, data<BR/>extraction and assimilation, statistical analyses, and review writing.</P>
<P>Regushevskaya Elena: protocol writing, searching, trial selection, data<BR/>extraction and assimilation, statistical analyses, and review writing.</P>
<P>Mayer Brezis: protocol writing, trial selection, data<BR/>extraction and assimilation, statistical analyses, and review writing.</P>
<P>Karla Soares-Weiser: protocol writing, trial selection, data<BR/>extraction and assimilation, statistical analyses, and review writing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-15 12:43:32 -0400" MODIFIED_BY="John K MacDonald">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Haens-2001" NAME="D'Haens 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al</AU>
<TI>Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120</VL>
<NO>6</NO>
<PG>1323-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11313301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Haens G, Lemmens L, Hiele M, Vandeputte L, Nevens F, Peeters M, et al</AU>
<TI>Intravenous cyclosporine (CyA) monotherapy versus intravenous methylprednisolone (MP) monotherapy in severe ulcerative colitis: a randomized, double blind controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>4 Part 2</NO>
<PG>A487</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Haens G, Lemmens L, Hiele M</AU>
<TI>Cyclosporine monotherapy versus methylprednisolone in severe ulcerative colitis: a randomized double-blind controlled trial</TI>
<SO>Acta Gastroenterol Belg</SO>
<YR>1998</YR>
<VL>61</VL>
<NO>1</NO>
<PG>C33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lichtiger-1994" NAME="Lichtiger 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al</AU>
<TI>Cyclosporine in severe ulcerative colitis refractory to steroid therapy</TI>
<SO>N Eng J Med</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>26</NO>
<PG>1841-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8196726"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Actis-1993" NAME="Actis 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Actis GC, Ottobrelli A, Pera A, Barletti C, Ponti V, Pinna-Pintor M, et al</AU>
<TI>Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids</TI>
<SO>J Clin Gastroenterol</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>1</NO>
<PG>10-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8409289"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Actis-1998" NAME="Actis 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R</AU>
<TI>Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>4</NO>
<PG>276-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9836079"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Actis-2004" NAME="Actis 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Actis GC, Lagget M, Rizzetto M, Fadda M, Palmo A, Pinna-Pintor M, et al</AU>
<TI>Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis</TI>
<SO>Minerva Med</SO>
<YR>2004</YR>
<VL>95</VL>
<NO>1</NO>
<PG>65-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15041927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atkinson-1997" NAME="Atkinson 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson KA, McDonald JW, Lamba B, Feagan BG</AU>
<TI>Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists</TI>
<SO>Can J Gastroenterol</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>7</NO>
<PG>583-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9395759"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baert-1994" NAME="Baert 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baert F, Hanauer S</AU>
<TI>CYA in severe steroid-resistant ulcerative colitis: long-term results of therapy</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>4 Part 2</NO>
<PG>A648</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breese-1995" NAME="Breese 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breese EJ, Michie CA, Nicholls SW, Williams CB, Domizio P, Walker-Smith JA, et al</AU>
<TI>The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>5</NO>
<PG>547-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8580276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbonnel-1996" NAME="Carbonnel 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Lemann M, et al</AU>
<TI>Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>12</NO>
<PG>2471-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9011460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbonnel-2000" NAME="Carbonnel 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, et al</AU>
<TI>Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3</NO>
<PG>273-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10735919"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1999a" NAME="Cohen 1999a" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RD, Brodsky AL, Hanauer SB</AU>
<TI>A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10028443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1999b" NAME="Cohen 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RD, Stein R, Hanauer SB</AU>
<TI>Intravenous cyclosporin in ulcerative colitis: a five-year experience</TI>
<SO>Am J Gastroenterol</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>6</NO>
<PG>1587-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10364029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermida_x002d_Rodriguez-99" NAME="Hermida-Rodriguez 99" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J</AU>
<TI>High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease</TI>
<SO>Hepatogastroenterology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>28</NO>
<PG>2265-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10521978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornbluth-1994" NAME="Kornbluth 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornbluth A, Lichtiger S, Present D, Hanauer S</AU>
<TI>Long-term results of oral cyclosporine in patients with severe ulcerative coloitis: a double blind, randomized, multi-center trial</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>4 Part 2</NO>
<PG>A714</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornbluth-1997" NAME="Kornbluth 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kornbluth A, Present DH, Lichtiger S, Hanauer S</AU>
<TI>Cyclosporin for severe ulcerative colitis: a user's guide</TI>
<SO>Am J Gastroenterol</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>9</NO>
<PG>1424-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9317057"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kozarek--1995" NAME="Kozarek  1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kozarek R, Bedard C, Patterson D, Justus P, Sandford R, Greene M, et al</AU>
<TI>Cyclosporin use in the precolectomy chronic ulcerative colitis patient: a community experience and its relationship to prospective and controlled clinical trials. Pacific Northwest Gastroenterology Society</TI>
<SO>Am J Gastroenterol</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>12</NO>
<PG>2093-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8540494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lichtiger-1990a" NAME="Lichtiger 1990a" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lichtiger S, Present DH</AU>
<TI>Preliminary report: cyclosporin in the treatment of severe active ulcerative colitis</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8706</NO>
<PG>16-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1973211"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lichtiger-1990b" NAME="Lichtiger 1990b" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lichtiger S</AU>
<TI>Cyclosporine therapy in inflammatory bowel disease: open-label experience</TI>
<SO>Mt Sinai J Med</SO>
<YR>1990</YR>
<VL>57</VL>
<NO>5</NO>
<PG>315-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2096729"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loftus-2003" NAME="Loftus 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loftus CG, Loftus EV, Sandborn WJ</AU>
<TI>Cyclosporin for refractory ulcerative colitis</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>2</NO>
<PG>172-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okamura-2003" NAME="Okamura 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Okamura S, Aoki H, Ohashi S, Urano F, Shimodaira M, Kanamori S, et al</AU>
<TI>Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis</TI>
<SO>Hepatogastroenterology</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>49</NO>
<PG>91-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12629999"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortiz-2000" NAME="Ortiz 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz V, Nos P, Aguilera V, Berenguer J, Ponce J</AU>
<TI>Cyclosporin in an oral microemulsion as the initial treatment of corticoid-refractory ulcerative colitis</TI>
<TO>Ciclosporina en microemulsion oral como tratamiento inicial de la colitis ulcerosa activa corticorrefractaria</TO>
<SO>Gastroenterol Hepatol</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>120-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10804688"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramakrishna-1996" NAME="Ramakrishna 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M</AU>
<TI>Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>3</NO>
<PG>296-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8708884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rayner-2003" NAME="Rayner 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rayner CK, McCormack G, Emmanuel AV, Kamm MA</AU>
<TI>Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>3</NO>
<PG>303-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12895214"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosselli-1996" NAME="Rosselli 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosselli M, Casa A, Oliva L, Orlando A, Cottone M</AU>
<TI>Treatment of acute a steroid-resistant ulcerative colitis with continuous venous infusion of cyclosporine</TI>
<TO>Trattamento dell'attacco acuto di colite steroido-resistente con ciclosporina in infusione venosa continua</TO>
<SO>Recenti Prog Med</SO>
<YR>1996</YR>
<VL>87</VL>
<NO>9</NO>
<PG>416-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9053956"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandborn-1992" NAME="Sandborn 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sandborn WJ, Tremaine WJ</AU>
<TI>Cyclosporine treatment of inflammatory bowel disease</TI>
<SO>Mayo Clin Proc</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>10</NO>
<PG>981-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandborn-1993a" NAME="Sandborn 1993a" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF</AU>
<TI>Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>2</NO>
<PG>242-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8432481"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandborn-1993b" NAME="Sandborn 1993b" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM</AU>
<TI>Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis</TI>
<SO>Am J Gastroenterol</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>5</NO>
<PG>640-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8480724"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandborn-1994" NAME="Sandborn 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al</AU>
<TI>A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1429-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8194687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-1995" NAME="Santos 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR</AU>
<TI>Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis</TI>
<SO>J Clin Gastroenterol</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>4</NO>
<PG>285-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7665815"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stack--1998" NAME="Stack  1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stack WA, Long RG, Hawkey CJ</AU>
<TI>Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>10</NO>
<PG>973-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9798801"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svanoni-1998" NAME="Svanoni 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svanoni F, Bonassi U, Bagnolo F, Caporuscio S</AU>
<TI>Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>4 Part 2</NO>
<PG>A1107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Assche-2002" NAME="Van Assche 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Assche G, D'Haens G, Noman M, Hiele M, Asnong K, Aerden I, et al</AU>
<TI>Randomized double blind comparison of 4 mg/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>4 Suppl 1</NO>
<PG>A81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Assche-2003" NAME="Van Assche 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al</AU>
<TI>Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>125</VL>
<NO>4</NO>
<PG>1025-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14517785"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vermeire-1996" NAME="Vermeire 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vermeire S, Rutgeerts P</AU>
<TI>Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>253-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winter-1993" NAME="Winter 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winter TA, Dalton HR, Merrett MN, Campbell A, Jewell DP</AU>
<TI>Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'</TI>
<SO>Scand J Gastroenterol</SO>
<YR>1993</YR>
<VL>28</VL>
<NO>8</NO>
<PG>701-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8210986"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf--2002" NAME="Wolf  2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolf JM, Lashner BA</AU>
<TI>Inflammatory bowel disease: sorting out the treatment options</TI>
<SO>Cleve Clin J Med</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>8</NO>
<PG>621-6, 629-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-15 12:43:32 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-15 12:43:32 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2008-07-15 12:43:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Alderson 2004" TYPE="BOOK">
<AU>Alderson P, Green S, Higgens JPT, editors</AU>
<SO>Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6. In: The Cochrane Library, Issue 1 2004</SO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blomberg-2000" NAME="Blomberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Blomberg B, Jarnerot G</AU>
<TI>Clinical evaluation and management of acute severe colitis</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>3</NO>
<PG>214-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumberg-2002" NAME="Blumberg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg D, Beck DE</AU>
<TI>Surgery for ulcerative colitis</TI>
<SO>Gastroenterol Clin North Am</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>219-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12122734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gornet-2003" NAME="Gornet 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, et al</AU>
<TI>Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>2</NO>
<PG>175-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12869077"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haslam-2000" NAME="Haslam 2000" TYPE="JOURNAL_ARTICLE">
<AU>Haslam N, Hearing SD, Probert CS</AU>
<TI>Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects</TI>
<SO>Eur J Gastroenterol Hepatol</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>6</NO>
<PG>657-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10912486"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hyde-1997" NAME="Hyde 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hyde GM, Jewell DP</AU>
<TI>Review article: the management of severe ulcerative colitis</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>3</NO>
<PG>419-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9218065"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hyde-1998" NAME="Hyde 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hyde GM, Thillainayagam AV, Jewell DP</AU>
<TI>Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?</TI>
<SO>Eur J Gastroenterol Hepatol</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>5</NO>
<PG>411-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9619388"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hyde-2001" NAME="Hyde 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ</AU>
<TI>Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications</TI>
<SO>Dis Colon Rectum</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1436-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11598471"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ina-2002" NAME="Ina 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ina K, Kusugami K, Shimada M, Tsuzuki T, Nishio Y, Binion DG, et al</AU>
<TI>Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11837932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kunz-1998" NAME="Kunz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kunz R, Oxman AD</AU>
<TI>The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7167</NO>
<PG>1185-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9794851"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mantzaris-1994" NAME="Mantzaris 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G</AU>
<TI>Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis</TI>
<SO>Am J Gastroenterol</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8273796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mantzaris-2001" NAME="Mantzaris 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al</AU>
<TI>A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis</TI>
<SO>Scand J Gastroenterol</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>9</NO>
<PG>971-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11521989"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pikarsky-2002" NAME="Pikarsky 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pikarsky A, Zmora O, Wexner SD</AU>
<TI>Immunosuppressants and operation in ulcerative colitis</TI>
<SO>J Am Coll Surg</SO>
<YR>2002</YR>
<VL>195</VL>
<NO>2</NO>
<PG>251-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12168973"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Podolsky--2002" NAME="Podolsky  2002" TYPE="JOURNAL_ARTICLE">
<AU>Podolsky DK</AU>
<TI>Inflammatory bowel disease</TI>
<SO>N Engl J Med</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>6</NO>
<PG>417-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12167685"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Probert-2003" NAME="Probert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A</AU>
<TI>Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>7</NO>
<PG>998-1002</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12801957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schreiber--1998" MODIFIED="2008-07-15 12:41:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Schreiber  1998" TYPE="JOURNAL_ARTICLE">
<AU>Schreiber S, Fedorak RN, Wild G, Gangl A, Targan S, Jacyna M, et al</AU>
<TI>Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>4 Part 2</NO>
<PG>A1108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz--1995" NAME="Schulz  1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Truelove-1955" NAME="Truelove 1955" TYPE="JOURNAL_ARTICLE">
<AU>Truelove SC, Witts LJ</AU>
<TI>Cortisone in ulcerative colitis; final report on a therapeutic trial</TI>
<SO>Br Med J</SO>
<YR>1955</YR>
<VL>2</VL>
<NO>4947</NO>
<PG>1041-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-D_x0027_Haens-2001">
<CHAR_METHODS>
<P>Country: Belgium<BR/>Single-center randomized controlled, double-blind trial<BR/>Intention to treat<BR/>8 days<BR/>N=30</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-70 <BR/>Included: Inpatients with severe steroid refractory UC<BR/>Excluded: patients treated with azathioprine for less than 3 months or if the dose was changed in the 4 weeks before the admission, with clinical activity score higher 10. <BR/>Excluded: patients with parasitic or Clostridium difficile toxins or enteropathogens in the stool. patients with uncontrolled hypertension, renal insufficiency, increased concentration of liver enzymes, active infection and pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>cyclosporine in a continuous infusion of 4 mg/kg per day in a 250-ml 0.9% NaCl vs. methylprednisolone 40 mg/day in 250 ml 0.9% NaCl</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>response to therapy (response to therapy was defined as clinical activity score less than 10).<BR/>Number of patients who required surgery.<BR/>Number of patients with adverse events.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lichtiger-1994">
<CHAR_METHODS>
<P>Country: USA randomized controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-65<BR/>Included: patients with UC without response to intravenous corticosteroid therapy after seven or more days, with clinical activity score of 10 or higher.<BR/>Excluded: patients with bacterial or parasitic pathogens in stools, positive test for Clostridium difficile toxin, septicemia, perforation of the bowel, megacolon, active fungal or viral infection, or uncontrolled hypertension, had mercaptopurine or azathioprine within the preceding two weeks. Patients with elevated hepatic enzymes, hyperbilirubinemia, renal dysfunction, low serum cholesterol concentration.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>cyclosporine 4 mg/kg per day by continuous infusion vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response to therapy as clinical-activity score less than 10.<BR/>Number of patient required colectomy.<BR/>Number of patient with adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Actis-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT, open study in 8 patients, no placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Actis-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective, not RCT,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Actis-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open not RCT of oral CsA , in pateints refractory to or depepdent on steroids. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atkinson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were not patients. They were gastroenterologists asked about their experience with CsA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baert-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, description of long-term results of open-lable trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breese-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT, study assessed cytokines in a group of UC patients some of which were treated with CsA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carbonnel-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, retrospective analysis of records</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carbonnel-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective, not RCT, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, clinical trial without randomization, assessing quality of life</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective, not RCT, 5 year experience from open trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hermida_x002d_Rodriguez-99">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kornbluth-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>DBTCT of patients in remission for maintenance. The patients did not have severe steroid refractory UC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kornbluth-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT. Review paper describing results of treatment with CsA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kozarek--1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were not patients. They were gastroenterologists asked about their practices.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lichtiger-1990a">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open-label trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lichtiger-1990b">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open-label trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loftus-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a report of the various trials of CsA and is not a trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okamura-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ortiz-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramakrishna-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>open, not RCT, pediatric</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rayner-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective, not RCT, open, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosselli-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label trial without randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandborn-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes patients with Crohn's disease, not RCT, open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandborn-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>the patients do not fit with the review specifications, they were not with severe UC but with associated sclerosing cholangitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandborn-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>patients did not have severe UC and were treated in an open fashion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandborn-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind placebo controlled trial (DBPCT) in patient with mild to moderate colitis in 4 dose regimens and placebo of CsA enemas. The patients were not in severe refractory colitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Santos-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, retrospective review of open-label trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stack--1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label clinical trial without randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svanoni-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of cyclosporine treatment with CsA + corticosteroids vs CsA. The trial was published in abstract form only, and was not blinded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Assche-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison cyclosporine with cyclosporine i n2 doses, not with standard treatment. therefore does not meet review specifications.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Assche-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind randomized controlled trial) DBRCT comparing 2 doses of CsA in severe UC. no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vermeire-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label trial without randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winter-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolf--2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>not RCT, open label trial without randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-D_x0027_Haens-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lichtiger-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Cyclosporine versus Placebo or Steroids</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>No induction of remission</NAME>
<GROUP_LABEL_1>Cyclosporine A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroids/Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav steroids/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7518584324444377" CI_START="0.29123590821248324" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.24349900794375787" LOG_CI_START="-0.5357550793002339" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="24753" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-D_x0027_Haens-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.20952380952380956" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6668024857060448" CI_START="0.07212288730218466" EFFECT_SIZE="0.21929824561403508" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.1760027898782153" LOG_CI_START="-1.1419268954506545" LOG_EFFECT_SIZE="-0.658964842664435" ORDER="24754" O_E="0.0" SE="0.5673886010146869" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="11" TOTAL_2="9" VAR="0.3219298245614035" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Need for a colectomy</NAME>
<GROUP_LABEL_1>Cyclosporine A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroids/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav steroids/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="24755" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-D_x0027_Haens-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.05841426734392" CI_START="0.18293187758688692" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3135327834079169" LOG_CI_START="-0.7377106080623171" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="24756" O_E="0.0" SE="0.6175055718883281" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="11" TOTAL_2="9" VAR="0.3813131313131312" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Cyclosporine A</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="24757" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Parasthesias</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroids/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav steroids/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="24758" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-D_x0027_Haens-2001" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="24759" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Cyclosporine A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroids/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav steroids/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24760" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-D_x0027_Haens-2001" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
<DICH_DATA CI_END="24.33841901402626" CI_START="0.4400755774432298" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3862923637139084" LOG_CI_START="-0.3564727324957841" LOG_EFFECT_SIZE="0.5149098156090622" ORDER="24761" O_E="0.0" SE="1.0237088443399314" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="11" TOTAL_2="9" VAR="1.047979797979798" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Cyclosporine A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroids/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav steroids/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24762" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-D_x0027_Haens-2001" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.329623961112182" CI_START="0.059085940530862205" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0542154955364644" LOG_CI_START="-1.2285158469742647" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="24763" O_E="0.0" SE="1.340887690293187" STUDY_ID="STD-Lichtiger-1994" TOTAL_1="11" TOTAL_2="9" VAR="1.797979797979798" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>